Treatment of Antiphospholipid Syndrome After First Provoked Venous Thrombosis
This protocol covers definite antiphospholipid syndrome (APS) presenting with a first provoked venous thrombotic event — such as lower limb deep vein thrombosis. The central clinical question is how to anticoagulate and for how long.
Confirmed APS with a first venous thrombosis that was provoked. Anticoagulation duration is shaped by standard guidelines for provoked venous thrombosis and adjusted according to the patient's antiphospholipid antibody (aPL) risk profile and individual recurrence risk factors.
Initial management involves parenteral anticoagulation followed by transition to an oral vitamin K antagonist. The recommended duration follows international guidelines for provoked venous thrombosis, though extended anticoagulation may need to be considered for patients with a high-risk aPL profile or additional recurrence risk factors. The complete regimen and decision algorithm are available in the full protocol.
References
DOI: 10.1136/annrheumdis-2019-215213
- In patients with APS and first venous thrombosis, after an initial therapy with unfractionated heparin (UFH) or LMWH and bridging therapy of heparin plus VKA, treatment with VKA with a target INR of 2–3 is recommended.
- In patients with provoked first venous thrombosis, therapy should be continued for a duration recommended for patients without APS according to international guidelines.
- Longer anticoagulation could be considered in patients with high-risk aPL profile in repeated measurements or other risk factors for recurrence.